`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`
`
`TEVA PHARMACEUTICALS USA, INC.,
`Petitioner,
`
`v.
`
`MONOSOL RX, LLC,
`Patent Owner.
`______________
`
`
`
`Case IPR2016-00281
`Patent 8,603,514 B2
`______________
`
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits the following current
`
`exhibit list:
`
`Exhibit No.
`
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`Description
`U.S. Patent No. 8,603,514 (filed July 10, 2007)
`
`File History, U.S. Patent No. 8,603,514
`
`Expert Declaration of Jayanth Panyam, Ph.D., Relating to U.S.
`
`Patent No. 8,603,514
`
`U.S. Patent No. 7,067,116 (filed Mar. 23, 2000) (“Bess”)
`
`WO 00/42992 (published July 27, 2000) (“Chen”)
`
`CA 2,274,910 (published June 25, 1998) (“Cremer”)
`
`File History of Reexam No. 95/002,170
`
`Alfred Martin, Physical Pharmacy (4th ed. 1993) (“Physical
`
`Pharmacy”)
`
`Joint Claim Construction Chart, Reckitt Benckiser Inc. v. Teva
`
`Pharmaceutical USA, Inc., CA. No. 14-01451-RGA (Nov. 17,
`
`2015), D.I. 91
`
`Trial Transcript, Reckitt Benckiser Inc. v. Watson Labs., Inc.,
`
`CA No. 14-1574-RGA (Nov. 3-4, 2015) (“Trial Tr.”)
`
`U.S. Patent No. 6,221,402 (issued April 24, 2001)
`
`C.S. Fuller et al., Interactions in poly(ethylene oxide)—
`
`
`
`
`2
`
`
`
`
`
`
`
`
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`hydroxypropyl methylcellulose blends, 42 Polymer 9583 (2001)
`
`Leon Lachman et al, The Theory and Practice of Industrial
`
`Pharmacy (1986) (“The Theory and Practice of Industrial
`
`Pharmacy”)
`
`J. Thuro Carstensen, Theory of Pharmaceutical Systems Volume
`
`II: Heterogenous Systems (1973) (“Theory of Pharmaceutical
`
`Systems”)
`
`Remington’s Pharmaceutical Sciences (Alfonso R. Gennaro, ed.,
`
`18th ed., 1990)
`
`Mixing in the Process Industries (N. Harnby et al., eds., 2nd ed.,
`
`1997)
`
`Sevim Kaya & Ahmet Kaya, Microwave drying effects on
`
`properties of whey protein isolate edible films, 43 Journal of
`
`Food Engineering 91 (2000)
`
`X.Z. Shu et al., Novel pH-sensitive citrate cross-linked chitosan
`
`film for drug controlled release, 212 International Journal of
`
`Pharmaceutics 19 (2001)
`
`T.J. Bowser & L.R. Wilhelm, Modeling Simultaneous
`
`Shrinkage and Heat and Mass Transfer of a Thin, Nonporous
`
`3
`
`
`
`
`
`
`
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`
`Film During Drying, Vol. 60 No. 4 Journal of Food Science 753
`
`(Nov. 4, 1995)
`
`U.S. Patent No. 6,596,298 (filed September 14, 1999)
`
`U.S. Patent No. 6,099,865 (filed June 11, 1999)
`
`U.S. Patent No. 5,166,233 (filed January 31, 1990)
`
`Jian-Hwa Guo & Horst Zerbe, Water Soluble Film for Oral
`
`Administration, The 24th International Symposium on
`
`Controlled Release of Bioactive Materials 227 (1997) (“Guo”)
`
`J.P. Cassidy et al., Controlled buccal delivery of buprenorphine,
`
`25 Journal of Controlled Release 21 (1993)
`
`U.S. Patent No. 4,849,246 (issued July 18, 1989)
`
`U.S. Patent No. 5,393,528 (filed June 1, 1993)
`
`U.S. Patent No. 5,948,430 (filed August 1, 1997) (“Zerbe”)
`
`U.S. Patent No. 5,629,003 (filed September 2, 1994)
`
`EP No. 0,090,560 (published May 3, 1989) (“Mitra”)
`
`Remington’s Pharmaceutical Sciences (John E. Hoover ed., 15th
`
`ed. 1975)
`
`Arlene Weintraub, It's On The Tip Of Your Tongue, Bloomberg
`
`(July 30, 2006),
`
`4
`
`
`
`
`
`
`
`
`
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1039
`
`1040
`
`http://www.bloomberg.com/bw/stories/20060730/
`
`itsonthetipofyourtongue
`
`U.S. Patent No. 6,552,024 (filed Nov. 5, 1999)
`
`WO 2001/70194 (published September 27, 2001)
`
`Curriculum Vitae of Jayanth Panyam, Ph.D.
`
`Materials Considered by Jayanth Panyam, Ph.D.
`
`S. Le Person et al., Near Infrared Drying of Pharmaceutical Thin
`
`Films: Experimental Analysis of Internal Mass Transport, 37
`
`Chemical Engineering & Processing 257 (1998) (“Le Person”)
`
`Decision on Appeal Regarding U.S. Patent 7,666,337, Appeal
`
`2014-00893
`
`Decision on Appeal Regarding U.S. Patent 7,824,588, Appeal
`
`2014-000547
`
`Decision on Appeal Regarding U.S. Patent 7,897,080, Appeal
`
`2014-007671
`
`Telephone Conference Transcript, Teva Pharmaceuticals USA,
`
`Inc. v. Monsol RX LLC and Indivior, IPR2016-00280,
`
`IPR2016-00281, and IPR2016-00282 (Feb. 17, 2016)
`
`5
`
`
`
`
`
`Pursuant to the Board’s directive during the parties’ February 17, 2016 call
`
`with the Board, Petitioner herewith files Exhibit 1040, Telephone Conference
`
`Transcript, Teva Pharmaceuticals USA, Inc. v. Monsol RX LLC and Indivior,
`
`IPR2016-00280, IPR2016-00281, and IPR2016-00282 (Feb. 17, 2016).
`
`
`
`Dated: February 26, 2016
`
`
`
`Respectfully submitted,
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Tel: 212-813-8800
`Fax: 212-355-3333
`
`Counsel for Petitioner
`
`
`
`
`6
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing: PETITIONER’S
`
`UPDATED EXHIBIT LIST and accompanying Exhibit 1040 were served
`
`electronically via e-mail on February 26, 2016 on the following:
`
`Daniel A. Scola, Jr.
`
`dscola@hbiplaw.com
`
`Michael I. Chakansky
`
`mchakansky@hbiplaw.com
`
`514ipr@hbiplaw.com
`
`By: /Cynthia Lambert Hardman/
` Cynthia Lambert Hardman
`(Reg. No. 53,179)
`
`7
`
`
`Dated: February 26, 2016